Results 171 to 180 of about 3,429 (181)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)

British Journal of Cancer, 2017
Sallie-Anne Pearson, Benjamin Daniels, Belinda Kiely   +2 more
exaly  

Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

Current Oncology, 2008
Mark Clemons, Dent S, Clemons M
exaly  

Paclitaxel/trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis

Cancer Treatment Reviews, 2011
Chun Liang, Shenhong Wu
exaly  

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Cancer, 2012
George Calin, Libero Santarpia, Lajos Pusztai   +2 more
exaly  

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilarPF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01)

British Journal of Clinical Pharmacology, 2014
exaly  

The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta‐analysis

Cardiovascular Therapeutics, 2018
, William K K Wu
exaly  

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

Annals of Oncology, 2007
Paul Hofman, E Chamorey, G Pages
exaly  

Trastuzumab

Reactions Weekly, 2008
openaire   +1 more source

Osimertinib/Trastuzumab-deruxtecan/Trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source